Compare Crispr Therapeutics AG (CRSP) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Raymond James Financial, Inc. — how do they compare? Crispr Therapeutics AG trades at $54.14 (market cap $5.23B), while Raymond James Financial, Inc. trades at $180.94 (market cap $34.63B). The key difference: Raymond James Financial, Inc. is far larger — about 6.6× Crispr Therapeutics AG's market cap, and Raymond James Financial, Inc. pays a 1.2% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | RJF | |
|---|---|---|
Market Cap | $5.23B | $34.63B |
Sector | Health | Financials |
52-Week High | $76.78 | $180.55 |
52-Week Low | $44.34 | $140.89 |
Enterprise Value | $3.65B | — |
Dividend Yield | — | 1.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.83, up 0.6% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by surging CASGEVY sales. However, financials show deep losses, with a net income margin of -4,101.26% in 2025 and negative operating cash flow, though financing activities provided liquidity.
The outlook is mixed: strong analyst consensus (57.9% buy ratings) and a $82.67 price target reflect optimism around CASGEVY growth and pipeline catalysts, but high valuation (P/S of 466.05) and persistent cash burn pose significant risks. Investment appeal hinges on successful clinical advancements and path to profitability.
Raymond James Financial (RJF) trades at $180.34, up 0.7% for the day, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust revenue growth, with 2025 revenue at $13.84B and net income of $2.14B, supported by a P/E of 15.69 and net margin of 15.37%. Recent news highlights record Q3 2026 results and a golden cross formation, indicating positive momentum.
Outlook is positive due to consistent earnings outperformance and analyst buy ratings, but risks include volatile cash flows from investing activities and reliance on capital markets strength. The consensus price target of $183.75 suggests modest upside, with institutional interest shown by CalPERS' recent share acquisition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
